Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: A comparative study of efficacy and safety

Abstract

Objective:To compare the efficacy and safety of olopatadine and rupatadine in seasonal allergic rhinitis (SAR).Materials and Methods:A 2-week, single-centered, randomized, open, parallel group comparative clinical study was conducted on patients with SAR. Following inclusion and exclusion criteria, 70 patients were recruited and were randomized to two treatment groups and received the respective drugs for 2 weeks. At follow-up, clinical improvement was assessed in terms of change in total and differential count of leucocytes, serum Immunoglobulin E (IgE) level, Total Nasal Symptom Score (TNSS) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scoring.Results:Both the drugs significantly reduced the differential count (P<0.001) and absolute eosinophil count (P<0.001), but olopatadine was found to be superior. In olopatadine group, there was significantly higher reduction in serum IgE (P=0.01), TNSS (P<0.001) and RQLQ score (P=0.015) than that of rupatadine. Incidence of adverse effects was found to be less in olopatadine group when compared with rupatadine group.Conclusions:Olopatadine is a better choice in SAR in comparison to rupatadine due to its better efficacy and safety profile.

Comparison of efficacy, safety, and cost-effectiveness of rupatadine and olopatadine in patients of allergic rhinitis: A prospective, randomized, double-blind, parallel group study

“…Other adverse events noted were headache and dryness of mouth which were also found in the previous study. [214] Our study did not reveal any change in electrocardiogram (ECG), supporting the previous studies which also showed no change in ECG findings. [101415]…”

“…Symptom severity was determined by the TNSS which consisted of sneezing, rhinorrhea, itching, and nasal congestion scored on a severity scale from 0 to 3 (0 = none, 1 = mild, 2 = moderate, and 3 = severe), such that the maximum possible TNSS was 12. [28]…”

“…AR is associated with sleep disturbances that result in impaired work productivity and interference with cognitive and emotional functioning. [2]…”

Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double‐blind, 6‐week trial

“…An increase in eosinophil count is the hallmark of late phases of allergic diseases. The scrupulous control of this parameter is an important therapeutic aim . Previous research found a greater reduction in eosinophil count with rupatadine compared with cetirizine, which suggests the superiority of rupatadine .…”

“…The scrupulous control of this parameter is an important therapeutic aim. 21 Previous research found a greater reduction in eosinophil count with rupatadine compared with cetirizine, which suggests the superiority of rupatadine. 22 Decreases in differential eosinophil count, TLC, and differential neutrophil count were revealed, whereas no significant differences in differential monocyte and basophil counts were seen in the rupatadine group.…”